General Assembly meeting of EIPICO company.
EIPICO will begin construction of its new plant with an investment of one Billion L.E. A Preference among 6 international companies to implement the construction.
Dr. Ahmed Kelani, Chairman and Managing Director of “ Egyptian international Pharmaceutical Industries company (EIPICO, announced that, company received the land of EIPICO-3 plant, which will be established for the production of preparations and biological alternatives. It is considered as a national project. It has a support and attention of the political leadership of the country. Because it represents a great addition in the field of providing highly sensitive and important medicines to citizens.
This project reflects the National and Social role of our company by providing the necessary medicines for citizens. EIPICO also contributed to the campaign named - 100 million health- last year. By providing about 40% of the drug for treatment of C virus.
EIPICO puts all its opportunities at the disposal of the Egyptian Ministry of Health against Corona Epidemic
Dr. Ahmed Kelani added that within the framework of the national and social responsibility of "EIPICO" pharmaceutical company, we have started implementing a package of policies aimed at supporting the efforts of the country in combating the coronavirus "covid-19".
He praised the continuous follow-up of the Ministry of Health and the Egyptian medicine authority to ensure the production and availability of the company's medicines on the market, and its cooperation to overcome any obstacles. To help for achieving company's duty for citizens to provide medicines, and also to fulfill its obligations and execute export contracts.
Dr. Ahmed Kelani presented to the members of the General Assembly of the company the achievements of "EIPICO " during 2019 in various fields. saying: "despite the challenges which, faced our company – such as - the high industrial costs and the stability of the prices of its preparations, the company was able to achieve all its production and sales targets" .
The company achieved production of 3,281 billion L.E. compared to 2,876 billion in 2018, with a growth rate of 14.1%, and the number of produced packs reached 330 million packs.
The sales volume of "EIPICO" reached 3,221 billion L.E. with a growth rate of 17.25%, and the growth of local sales reached 23.3% - that’s exceed the growth rate of the Egyptian market, which reached 16.1% in 2019.
EIPICO exports increased to about 38,149 million USD , with a growth rate of 3.94% achieving the first place in Egypt, and 21% of Egypt's total exports of Medicine. EIPICO exports to 66 countries all over the world.
EIPICO is at the top of the market for ophthalmic products in Egypt in terms of the number of units, with 27% of the units sold in the Egyptian market of these products in 2019, and with a growth rate of 13 % in sales value while the market sales growth rate reached 5 % last year. He pointed out that "EIPICO" has contracted for the production line of single-dose ophthalmic products, which will gain the company's preparations a major competitive advantage in this market .
March 28th, 2020